Delivering Unprecedented Access to Biosimilars in Global Markets
  • Building a pure-play, sustainable and profitable
    biosimilar business
  • Improving patient access to important, cost-effective
    medicines worldwide
  • Advancing our products through strategic partnerships
    to maximize future value
Who We Are

EPIRUS is a biopharmaceutical company focused on building a pure-play, sustainable and profitable biosimilar business by improving patient access to cost-effective medicines worldwide. Currently, we are progressing a pipeline of three monoclonal antibodies for autoimmune / inflammatory conditions. Our focus is to effectively navigate the diverse regulatory, legal and commercial global landscape for biosimilars through strategic partnerships which will maximize future value.

Learn More


July 14, 2015

EPIRUS Biopharmaceuticals and Polpharma Group Enter Into a Multi-Product, Multi-Region, Profit-Sharing Collaboration to Advance Biosimilar Portfolio Targeting $6 Billion Addressable Innovator Market

June 10, 2015

EPIRUS Biopharmaceuticals Presents New BOW015 (Infliximab Biosimilar) Data at the European League Against Rheumatism Annual Congress (EULAR 2015)


July 14 2015

EPIRUS Announces Profit-Sharing Collaboration with Polpharma Group

May 14, 2015

EPIRUS Presents at Bank of America Merrill Lynch Healthcare Conference

Bookmark and Share